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There is an urgent need for antitumor bioactive agents with minimal or no side effects over 
normal adjacent cells. Fucoidan is a marine-origin polymer with known antitumor activity. 
However, there are still some concerns about its application due to the inconsistent experi-
mental results, specifically its toxicity over normal cells and the mechanism behind its action. 
Herein, three fucoidan extracts (FEs) have been tested over normal and breast cancer cell 
lines. From cytotoxicity results, only one of the extracts shows selective antitumor behavior 
(at 0.2 mg mL−1), despite similarities in sulfation degree and carbohydrates composition. 
Although the three FEs present different molecular weights, 
depolymerization of selected samples discarded Mw as the 
key factor in the antitumor activity. Significant differences in 
sulfates position and branching are observed, presenting FE 2 
the higher branching degree. Based on all these experimental 
data, it is believed that these last two properties are the ones 
that influence the cytotoxic effects of fucoidan extracts.
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1. Introduction
Cancer can have various origin-factors, being characterized 
by uncontrolled cell growth and spread.[1] Cancer thera-
peutics aim to increase the survival time and the quality-
of-life of the patients. The goal of cancer treatment is the 
extinction of tumor cells, ideally with minimal damage to 
healthy tissues. The toxic effects over normal cells often 
limit the current chemotherapeutic agents used in cancer 
treatments, which conduct to reduced dosage and, conse-
quently, efficacy of the treatment.[2,3]
Breast cancer is the second most frequent diag-
nosed cancer and the first among females.[4] If breast 
cancer is detected in an early stage, there is a possi-
bility to be treated and removed surgically. However, 
the treatment of the advanced stage breast cancer is 
often followed by reoccurrence and can become fatal, 
even when chemotherapeutic agents are administered. 
There are several factors such as tumors heterogeneity, 
drug resistance, side effects, and toxicity to healthy tis-
sues, that diminish the efficacy and usefulness of this 
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treatment.[5,6] Therefore, there is a strong interest in 
developing better-tolerated anticancer agents and treat-
ment modalities.[7]
Because of the side effects of many current treatments, 
the use of natural substances with low toxicity is of 
great interest.[8] Natural-derived polymers are of special 
interest due to their biological and chemical similari-
ties to natural tissues composition. Marine organism are 
valuable sources of materials with intriguing properties 
and characteristics.[9] Among marine-origin materials, 
fucoidan is a polysaccharide that consists of sulfated 
fucose residues and is possible to be extracted from 
brown seaweeds of different species such as Fucus vesicu-
losus, Laminaria japonica, and Undaria pinnatifida.[10–12] 
Fucoidan has been reported to have various biological 
activities including antibacteria, antioxidant, antiviral, 
and antitumor.[13,14]
Fucoidan antitumor behavior has been demonstrated 
in vitro and in vivo for different type of cancers such as 
breast, lung, prostate, colon, and melanoma.[7,15–18] It 
retards tumor development, eradicating tumor cells by 
targeting key apoptotic molecules. Furthermore, the syn-
ergistic effect of fucoidan with current anticancer agents 
has also been reported.[8,19] Despite the promising results 
about its anticancer effects, the fucoidan mechanism 
of action is not clearly understood and thus, fucoidan 
has not yet been developed as a regulated therapeutic 
agent.[20,21] The main barriers to its utilization in clinic 
are: (i) its toxicity to normal cells, and (ii) the variable and 
contradictory results in fucoidan usage.[8,22] In addition, 
there are a huge variety of algae fucoidan sources, which 
implies various extraction and purification methods that 
may influence fucoidan’s intrinsic properties and its bio-
activity such as molecular weight, carbohydrates compo-
sition, and sulfation. Molecular weight has been reported 
as one of the main factors influencing fucoidan anti-
tumor behavior. From previously reported works, lower 
molecular weight fucoidan presents higher antitumor 
effects whereas higher sulfation degree has been related 
with enhanced bioactivity responses.[23,24] However, most 
studies analyzing antitumor activity did not characterize 
in detail the composition of the used fucoidan and this is 
probably the cause of some contradictory findings.[10,14,25]
An effective cancer therapeutic strategy is character-
ized by the ability to eliminate tumors without damaging 
healthy tissues. Due to the different properties affecting 
fucoidan bioactivity, there is the need to evaluate the 
antitumor effects of a certain extract and characterize 
which feature(s) is (are) playing the major role. For that 
purpose, herein, three different extracts from the same 
species (i.e., F. vesiculosus) were tested with human breast 
cancer cells, and normal endothelial and fibroblastic cells. 
From these biological data we were able to observe three 
completely different bioactive responses and, in that 
sense, we decided to carry out structure–activity relation-
ship studies.
2. Results
2.1. Cytotoxicity of Fucoidan Extracts
2.1.1. Fucoidan Extract 1 (FE 1) Does Not Present  
Toxic Effects over Cancer Cells and Shows Toxicity  
for Normal Cells
FE 1 presents cytostatic effects at day 2 and day 3 for MDA-
MB-231 cell line as demonstrated by the inhibited cells 
growth when compared to the control and lower concen-
trations (Figure 1A). Regarding MCF-7 cell line, fucoidan 
presents toxic effects only at day 3 and at concentration of 
5 mg mL−1 (Figure 1B). Cytotoxic assays for the normal cells 
showed cytotoxic effect at day 2 for concentrations above 
2 mg mL−1 (Figure 1C,D).
2.1.2. FE2 Induces Cancer Cells Death but Does Not Affect 
the Viability of Normal Cells at 0.2 mg mL−1
We began to test FE2 at the same concentrations as the FE1. 
However, a significant effect of fucoidan over the breast 
cancer cell lines was revealed at low concentrations: at 
day 2 and at concentration of 0.2 mg mL−1, the fucoidan 
induces cell death for both MDA-MB-231 and MCF-7 cell 
lines (Figure 2A,B). This effect become more pronounced at 
higher fucoidan concentrations. The two types of normal 
cells show distinct behavior: cytostatic effect for the 
endothelial cells was observed at day 2 and at concentra-
tion of 0.5 mg mL−1 (Figure 2C), while, for fibroblastic cells 
this effect was seen above concentration of 0.3 mg mL−1 
(Figure 2D).
These results demonstrated that FE2 induces apoptosis 
for the two types of tumor cells above 0.2 mg mL−1 and 
maintains the viability of normal endothelial and fibro-
blastic cells at the same concentration.
2.1.3. FE3 Is Toxic to Both Cancer and Normal Cells
Similar to FE2, FE3 induces cancer cells death at day 1 for 
concentrations above 0.2 mg mL−1 (Figure 3A,B). However, 
fucoidan extract 3 (FE 3) affects also the normal cells at 
this concentration and thus, its effect differs from FE2. 
Stronger cytostatic effect was observed for endothelial 
cells (Figure 3C): significantly diminished proliferation 
was measured for the cells at 0.1 mg mL−1 concentration 
and significant cytotoxic effect is observed above concen-
tration of 0.3 mg mL−1. Concerning the fibroblastic cells, 
fucoidan has severe consequences over this cell type and 
the cytotoxic effect is observed for concentration above 
0.2 mg mL−1 (Figure 3D).
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Figure 1. Cytotoxicity of FE 1, at different concentrations and time-points (1, 2, and 3 days), over human cell lines A) MDA-MB-231, B) MCF-7, 
C) HPMEC-ST1.6R, and D) MRC-5. Data were considered statistically different if p < 0.05. * indicates significant differences when compared 
to + control; +, when compared to 0.1 mg mL−1; x, when compared to 0.5 mg mL−1; o, when compared to 1 mg mL−1; &, when compared to 
2 mg mL−1, and $, when compared to 3 mg mL−1.
Figure 2. Cytotoxicity of FE 2, at different concentrations and time-points (1, 2, and 3 days), over human cell lines A) MDA-MB-231, B) MCF-7, 
C) HPMEC-ST1.6R, and D) MRC-5. Data were considered statistically different if p < 0.05. * indicates significant differences when compared 
to + control; +, when compared to 0.1 mg mL−1; x, when compared to 0.2 mg mL−1; o, when compared to 0.3 mg mL−1, and &, when compared 
to 0.4 mg mL−1.
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2.2. Physicochemical Characterization of the Different 
Fucoidan Extracts
2.2.1. Molecular Weight
The gel permeation chromatography (GPC) analysis 
showed that the three extracts have significantly different 
molecular weight. A smallest retention volume (longer 
chain) was determined for FE 1 (Figure 4A,B). The molec-
ular weight of FE 1 is two times higher when compared 
with FE 3. All the three extracts have a very similar Mw/Mn 
(polydispersity).
5-([4,6-Dichlorotriazin-2-yl]amino)fluorescein hydro-
chloride (DTAF)-Labeled Fucoidans’ Cellular Internaliza-
tion: An internalization assay was performed to assess 
if cancer cells were able to internalize the FE based on its 
molecular weight. In that sense fucoidan extract 2 (FE 2) 
(the one with selective bioactivity) was compared with 
FE 1 (no bioactive activity and higher molecular weight). 
No green labeling is observed for the positive controls and 
DTAF (Figure 5) showing that DTAF alone is not internal-
ized by breast cancer and endothelial cells. Endothelial 
cells cultured with labeled FE 1 and FE 2 do not present 
any green fluorescence, i.e., DTAF-labeled fucoidan was 
not internalized by these cells. On the other hand, breast 
cancer cells internalized the labeled fucoidan: green 
staining localized near to the nucleus is visible in Figure 5 
for both FE 1 and FE 2.
FE 1 Hydrolysis: The above results (Figures 4 and 5) did not 
lead straightforward to any conclusions about the signifi-
cance of molecular weights on fucoidans bioactivity. How-
ever, since many authors related the Mw with the antitumor 
activity we performed further analysis about its influence. 
The FE 1 (the one with higher molecular weight) was hydro-
lyzed by an acidic reaction in boiling water to lower mole-
cular weight polymer and we further 
analyzed it. We obtained a polymer with 
molecular weight of 40 kDa (Figure 6A). 
This molecular weight is similar to the 
one of FE 3 that has toxic effect over both 
cancer and normal cells. The toxicity of 
this new polymer (FE 1*) was evaluated 
with breast cancer and endothelial cells 
and demonstrated no significant differ-
ences as compared with the initial FE1 
(Figure 6C,D vs Figure 1B,C).
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Figure 4. A) Molecular weight (Mw) and Mw/Mn of FE 1, FE 2, and FE 3 measured by GPC, 
B) molecular weight chromatograms.
Figure 3. Cytotoxicity of FE 3, at different concentrations and time-points (1, 2, and 3 days), over human cell lines A) MDA-MB-231, B) MCF-7, 
C) HPMEC-ST1.6R, and D) MRC-5. Data were considered statistically different if p < 0.05. * indicates significant differences when compared 
to + control; +, when compared to 0.1 mg mL−1; x, when compared to 0.2 mg mL−1; o, when compared to 0.3 mg mL−1, and &, when compared 
to 0.4 mg mL−1.
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2.2.2. Carbohydrates Composition
The obtained results for the monomeric composition of the 
analyzed sulfated-polysaccharides (Table 1) showed that 
the predominant sugar was the fucose (71.2%–79.1% mol), 
as expected. The following sugars are the uronic acids 
(9.8%–15.3% mol), xylose (3.9%–8% mol), galactose 
(3.5%–5.5% mol), and minor amounts of mannose and 
glucose. It seemed that there are not much differences 
between the analyzed fucoidan extracts. When comparing 
Macromol. Biosci. 2017,  DOI: 10.1002/mabi.201600340
Figure 5. Internalization of DTAF-labeled FE 1 and FE 2 by HPMEC-ST-1-6R and MCF-7 cell lines. In MCF-7 cultures, the nucleus staining by 
DAPI was omitted in face of the colocalization of internalized DATF-labeled fucoidans.
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one of the previous referred extracts with FE 1 (no toxicity 
over cancer cells) we often find comparable values, with 
at least one of the extracts (FE 2 and FE 3). The total sugar 
mass per extract mass is also very similar for the three 
extracts. Having a closer look into the quantification of 
neutral sugars and uronic acids, and having in mind that 
FE 2 and FE 3 are the ones that present toxicity to cancer 
cells, it is not possible to find any correlation between 
these sugar components and the anticancer activity.
2.2.3. NMR Spectroscopy
The differences in the biological activity observed in FE 
seems to be unrelated to the Mw and sugars composition 
therefore we decided to analyze in detail the sulfation and 
branching of the samples. The fastest way to compare the 
three extracts and obtain a general idea of the differences 
in composition is 1H NMR. The 1H NMR of the three sam-
ples at 400 MHz is included in Figure 7.
The spectra correspond to the previously described 
for fucoidan samples with the isolated regions of the 
fucose methyl protons (H6, 1–1.5 ppm), acetyl protons 
(at 2.2 ppm with a small proportion 0.5 to 1 acetyl groups 
per every 10 fucose residues) and anomeric (5.0–5.5 ppm) 
and a highly overlapped region corresponding to all other 
signals in the fucose 1H NMR[26] The strong overlap ham-
pers a very detailed information but the three extracts 
show enough differences to expect considerable different 
composition. Especially interesting was difference the 
region around 3.9–4.3 ppm that contains signals attrib-
uted to branched fucose.[27] In light of these results a 
detailed study of sulfation position and branching was 
performed by methylation analysis.
2.2.4. Sulfation Degree and Methylation Analysis
Sulfation is another key factor in fucoidan bioactivity: 
higher sulfation degree is often associated with greater 
bioactivity.[28] Quantification results demonstrate that the 
studied extracts have a very similar total percentage of 
sulfates, which varies between 28.0% and 29.3%. The anal-
ysis of partially methylated alditol acetates before (native) 
and after desulfation (desulfated) of fucoidans allow to 
know the substitution of sugar residues, corresponding to 
Table 1. Carbohydrates composition of the three fucoidan extracts.
% total sugar mass/
extract mass
% molar of neutral sugars % molar of uronic acids
Fucose Xylose Mannose Galactose Glucose
FE1 52.5 ± 2.5 73.1 ± 0.4 8.0 ± 0.1 1.3 ± 0.2 3.5 ± 0.3 0.7 ± 0.1 13.3 ± 0.3
FE2 52.2 ± 1.9 79.1 ± 0.6 3.9 ± 0.0 0.8 ± 0.0 5.5 ± 0.1 0.8 ± 0.0 9.8 ± 0.5
FE3 50.5 ± 2.7 71.2 ± 0.5 5.3 ± 0.1 1.5 ± 0.3 5.4 ± 0.0 1.3 ± 0.9 15.3 ± 0.8
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Figure 6. A) Molecular weight (Mw) and Mw/Mn measured by GPC, B) molecular weight chromatogram. Cytotoxicity of FE 1* over C) MCF-7 
and D) HPMEC-ST-1.6R cell lines. No statistical significant differences were observed.
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branching points and the substitution by sulfate esters. 
When a position is acetylated in the native polysaccharide 
and become methylated after desulfation, it is indication 
that this position contains a sulfate residue. However, 
when a position is acetylated even after desulfation of the 
polysaccharide, it can be inferred that it is a branching 
point. The results are shown in Table 2.
In native fucoidan extracts, 2,3,4-Fuc was the major 
residue for the three extracts, followed by 2,4- and 2,3-Fuc 
(coeluated peaks) residues, indicating a high percentage 
of substituted fucose. After desulfation it was observed 
the decrease of these specific residues (75%–80% for 
2,3,4-Fuc and 46%–61% for 2,4-Fuc + 2,3-Fuc), meaning 
that part of the substituents was sulfate esters that were 
removed with the desulfation procedure. An increase 
mainly of the 4-Fuc and 3-Fuc residues after desulfation 
allowed to infer that the fucoidan backbone was con-
stituted by these linkages, which is in accordance with 
literature, reporting that F. vesiculosus fucoidan main 
chain is composed of alternating 4-O and 3-O fucose link-
ages.[29,30] These results allowed also to conclude that sul-
fate esters were mainly linked in 2-O fucose. However, the 
observation of the 2-O linkage in the desulfated sample 
shows that this linkage should be also a characteristic of 
the fucoidan structure. The increase of 3,4-Fuc residues 
after desulfation, as well as the maintenance of about 
10% of 2,3,4-Fuc, 2,4-Fuc, and 2,3-Fuc branched residues, 
corroborate the presence of a branched fucoidan structure 
mainly in 3-O or 4-O positions. As the sum of all branched 
residues is equal to the sum of terminal residues of Fuc, 
Xyl, and UA (GlcA and GalA), it can be inferred that the 
fucoidan had a polymeric nature (no extra Fuc terminal 
residues), containing fucose, xylose, and uronic acids as 
side chains terminal residues.
The branching degree (sum of branched Fuc/(total Fuc 
minus the terminal Fuc), indicates the frequency (%) of 
side chain residues present in the backbone. Therefore, 
this structural feature of the polysaccharides was deter-
mined for FE 1, FE 2, and FE 3 and allowed to show that 
FE 2 was more branched (83.4%) than FE 1 (67.5%) or FE 3 
(60.4%) (Table 2).
Macromol. Biosci. 2017,  DOI: 10.1002/mabi.201600340
Figure 7. 1H NMR spectra (400 MHz, D2O, 25 °C) of the fucoidan 
extracts: FE1 bottom, FE 2 middle, and FE 3 top.
Table 2. Sulfation degree (%), glycosidic-substitution composition (%) of fucoidan samples in fractions FE 1, FE 2, and FE 3, before and after 
desulfation.
Sulfation degree (% sulfate mass/extract mass) FE 1 FE 2 FE 3
Sugar residues and substitution positions 28.0 ± 1.4 29.3 ± 2.8 28.6 ± 1.9
Native Desulfated Native Desulfated Native Desulfated
t-Fuc 5.5 14.2 4.2 13.1 4.7 13.4
4-Fuc 0.9 10.6 1.9 7.6 1.5 11.0
3-Fuc 1.5 9.3 1.2 7.3 1.5 13.6
2-Fuc 5.1 8.8 3.9 5.2 4.1 5.7
3,4-Fuc 3.9 12.3 7.3 11.2 5.8 9.2
2,4-Fuc + 2,3-Fuc 19.1 10.3 24.8 10.6 27.6 10.7
2,3,4-Fuc 42.8 9.1 42.9 11.3 34.8 6.8
Total Fuc 78.8 74.6 86.3 66.3 79.9 70.4
t-Xyl 6.8 9.1 3.3 7.7 4.4 8.2
t-GlcA + t-GalA 14.5 16.3 10.4 26.0 15.6 21.4
Branching degree [%] 67.5 83.4 58.9
Sulphate [%] 4-O linkage 30.5 27.4 38.5
3-O linkage 34.9 29.4 27.7
2-O linkage 55.6 50.9 60.3
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The percentage of sulfate present in each fucose posi-
tion (4-,3-, and 2-O linkage) was determined based on 
the increase of each fucose linkage after desulfation in 
relation to the native fucoidan (Table 2). The major per-
centage of sulfate esters was present in the 2-O-Fuc for 
all extracts (51%–60%), which is in agreement with lit-
erature.[29,30] In addition, it is also possible to observe 
the presence of sulfates in 3-O position (28%–35%) and 
4-O position (27%–36%). The FE 2 showed the presence of 
fewer sulfate esters in 4-O and 2-O positions when com-
pared with the other extracts, in opposite to FE 3 that had 
a higher percentage of sulfates in 4-O and 2-O positions. 
FE 1 had a higher content of sulfate in 3-O position.
3. Discussion
Fucoidan has been reported to inhibit the growth of 
cancer cells, having a great interest in the development 
of new cancer therapies.[24] When considering a cancer 
therapy, the ultimate goal is to affect cancer cells 
without damaging the surrounding healthy environ-
ment, having non or minimal side-effects.[31] The tumor 
microenvironment comprises not only the cancer cells 
but also the noncancerous cells which includes endothe-
lial cells, fibroblasts, and circulating immune cells.[32,33] 
For this reason, it is of utmost importance to test 
whether fucoidan can only damage the tumor cells and 
not the healthy surrounding tissues. The three fucoidan 
extracts were tested with endothelial, fibroblastic and 
breast cancer cells. When designing a blood adminis-
tered drug, there is a need to assure that its circulation 
will not affect the blood vessels. Therefore, we tested the 
cytotoxicity of fucoidan over human endothelial cells 
(HPMEC-ST-1.6R cell line). The healthy tissue around 
the tumor should not be affected when the drug enters 
into the interstitial fluid. Therefore, fucoidan should not 
affect this type of cells as well, herein represented by 
human fibroblasts (MRC-5 cell line). Breast cancer is one 
of the most frequent cancers and, as many other types of 
cancer, presents heterogeneous behavior. We used two 
different breast cancer cells lines to depict this tumor 
heterogeneity. MCF-7 cell line is an ideal cell model to 
study hormone responsive tumors since it is estrogen 
receptor (ER)-positive cells and forms tumors in the 
presence of estrogen.[34,35] On the other hand, MDA-MB-
231 cell line is ER-negative and have been shown to be 
tumorigenic.[34]
As previously stated, the desired effect of a cancer 
therapeutic strategy is that fucoidan has toxicity over 
cancer cell and no or diminished effects over noncancer 
cells. Some publications only show the effects of fucoidan 
over cancer cells.[19,36] However, this can lead to some 
misinterpretation of fucoidans’ antitumor activity, since 
it could also have toxic effects over normal cells. In the 
present study, we denoted that not all fucoidan extracts 
present this desired behavior. Specifically, FE 1, despite 
the wide range of concentrations, showed toxicity to 
normal cells at lower concentrations than cancer cells, 
resulting in an extract without antitumor features and 
not suitable for cancer therapies. On the other hand, both 
FE 2 and FE 3 presented toxicity to cancer cells, although 
FE 3 also presented toxicity to normal fibroblast cells at 
the same concentrations. Therefore, FE 3 has to be used 
with extreme careful and in a more target and precise 
way to try to affect only the cancer cells and diminished 
the toxic effects over noncancer cells, by not affecting the 
surrounding environment.[37] The FE 2 is the one with 
the desired antitumor behavior, since it showed toxicity 
effects over cancer cells at 0.2 mg mL−1 and, at this con-
centration, neither endothelial nor fibroblastic cells were 
affected. From this first group of results, we conclude 
that not all fucoidans present desirable features, leading 
to different toxic profiles when in contact with the same 
cells.
After this biological screening, the next step was 
focused on the physicochemical characterization of the 
three extracts, trying to understand which feature(s) 
play(s) a pivotal role in this antitumor behavior. As pre-
viously reported, the physicochemical factors that may 
influence fucoidan bioactivity are the molecular weight, 
monosaccharide composition, sulfates degree, and sul-
fates position. Nevertheless, despite not being directly 
related with fucoidan intrinsic structure the source and 
extraction method have also been described to influence 
its bioactive behavior.[10,14,28,38]
The effect of molecular weight has been reported as 
the crucial factor for the fucoidan bioactivity. Previous 
in vitro studies showed that lower molecular weight 
fucoidan significantly increased the anticancer activity of 
fucoidan.[23,36,39] Furthermore, it has been described that 
even with higher amounts of sulfation, molecular weight 
plays a more decisive role.[24] Among the fucoidans 
studied in the present work, FE 1 has the highest molec-
ular weight when compared with FE 2 and FE 3, but the 
latter are the ones presenting toxicity to breast cancer 
cells. Molecular weight is known to be associated with 
cell internalization, among other factors, from which we 
hypothesized that when comparing FE 2 with FE 1, only 
FE 2 (lower molecular weight) would be internalized by 
cancer cells and exert its antitumor action.[40,41] However, 
as illustrated in Figure 5, no differences were observed in 
the cellular internalization of FE 1 and FE 2. Thus, these 
results do not give any conclusions regarding the relation-
ship between cellular internalization and the molecular 
weight for the studied system.
It has been described that hydrolyzed fucoidan exhib-
ited a higher percentage of anticancer activity.[24,38] In 
Macromol. Biosci. 2017,  DOI: 10.1002/mabi.201600340
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particular, hydrolyzed fucoidan under mild conditions 
(in boiling water with HCl) showed higher antitumor 
activity whereas hydrolyzed fucoidan generated under 
harsh conditions (microwave) slightly enhanced the 
anticancer effects.[24] In this sense, FE 1 was hydrolyzed 
by acidic reaction to assess if the resulting fucoidan, 
FE 1*, with lower molecular weight, would present tox-
icity over cancer cells. However, as seen in Figure 6, this 
lower molecular weight extract did not present tox-
icity to normal and cancer cells. It has been described 
that acidic hydrolysis can reduce also sulfate content 
and depolymerization could change monosaccharides 
ratio, as, e.g., decreasing the level of uronic acids.[39,42] 
Besides, by comparing FE 1* and FE 3 it is possible to 
conclude that despite having similar molecular weight 
the two extracts present significant differences in their 
bioactivity response. These results suggest that the 
antitumor behavior may be related with other factors 
and not directly associated with fucoidans’ molecular 
weight.
The studied fucoidan extracts have a total percentage 
of carbohydrates between 50.5 and 52.5 and of sulfates 
between 28.0 and 29.3, which means that the total 
amount of polysaccharides present in the samples varies 
between 78.5% and 81.8%. These results confirm that 
fucose and sulfates are the main components of fucoidan 
from F. vesiculosus, as described elsewhere.[25,43] The 
uronic acids content has been determined in fucoidan 
composition, although we need to be cautious in 
assuming that the full uronic acid measured is contained 
within the fucoidan polymers, as has been described else-
where.[44] The carbohydrates composition did not indicate 
any clear structure-activity relationship (SAR).
Higher sulfation is related with greater molecular bio-
activity and thus researchers have produced over-sul-
fated fucoidans to enhance its biological properties.[29] 
It has been suggested that over-sulfation causes higher 
negative charge in the molecule, which facilitate forma-
tion of fucoidan-protein complexes involved in cell pro-
liferation.[31] Sulfate mass quantification of the three 
fucoidan extracts did not present significant variation. 
Despite these results, sulfates can still play a role in the 
antitumor activity, since the same sulfation degree can 
correspond to different sulfates position, i.e., sulfation 
distribution along fucoidan backbone, presenting dis-
tinct biological response. Thus, both sulfates position and 
polymer branching were assessed to better understand 
the role of the chemical structure on the exhibited biolog-
ical activity. The FE 2 was the polysaccharide with higher 
percentage of fully branched chains (together in 3-O and 
4-O-Fuc) and, as a consequence, it is a more branched 
structure than the other ones. Also, as all hydroxyl groups 
are linked, they could not have sulfates in these residues. 
The sulfates occur mainly in 2-O-Fuc. In comparison with 
FE 2, FE 1 had higher sulfation in 4-O-Fuc and 3-O-Fuc 
while FE 3 had higher sulfation in 4-O-Fuc. Consequently, 
the sulfates position is different for the three fucoidans. 
It is possible that these structural differences may influ-
ence their cytotoxicity response, particularly regarding 
the breast cancer cell lines tested.
It is thus shown here that the antitumor behavior is 
not ubiquitous, as could be inferred from the published 
reports, but dependent on their chemical structure, 
being also important to highlight that the same fucoidan 
extract can present different effects over different types 
of cells and cancers.[15]
As referred before, the source (original species) and 
extraction method are two factors that may affect fucoidan 
intrinsic properties and that are commonly associated 
with fucoidans’ bioactivity. Fucoidan preparations isolated 
from different sources have shown differential anticancer 
effects in vivo due to corresponding structural proper-
ties.[22] Since the source of fucoidan is the same for the 
three extracts (i.e., F. vesiculosus), the extraction method 
may be the factor influencing fucoidan intrinsic properties 
and thus the different antitumor behavior. Even from the 
same company, we have different batches that can pre-
sent different behaviors. The preservation of the fucoidan 
molecules’ structural integrity essentially depends on the 
extraction methodology which has a crucial, but partly 
ignored, significance for obtaining the relevant structural 
features required for specific biological activities and for 
elucidating structure–function relations.[14]
To be suited to a regulated product, fucoidan extracts 
must be defined and reproducible. Sustainable, clean, 
and regulated harvesting, or culturing of a single type of 
seaweed are required. In order to meet therapeutic regu-
latory requirements, common extraction methods and 
distributions of fully characterized fucoidans need to be 
taken into consideration. This is particularly relevant 
when trying to take a product from a preclinical concept 
to clinical trials. The development and use of such con-
sistent extraction procedures would also help in achieving 
a better understanding of structure–activity relationship 
of fucoidan extracts.
4. Conclusions
Despite the promising results about the anticancer 
effects of fucoidan, some variability impedes its utiliza-
tion in the clinic. Specifically, contradictory experimental 
results influenced by endogenous and exogenous factors 
in fucoidan usage are the main barriers. It is also impor-
tant to have in mind that the ultimate goal of an effec-
tive cancer therapy is to damage cancer cells without 
negatively affect the surrounding healthy environment. 
This distinctive action mode was only observed with the 
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FE 2 being important to characterize the physicochemical 
properties of the different extracts. The present results 
allow to infer that the molecular weight, monosaccharides 
composition, and content of sulfates could not be related 
with the cytotoxicity of FE 1, FE 2, and FE 3 extracts. From 
our results, we can conclude that the branching degree of 
the fucoidans may be the most obvious cause of the dif-
ferent biological behavior of the three extracts.
In this sense, more focus should be direct to the opti-
mization and standardization of the extraction and puri-
fication processes to obtain consistent protocols that 
account for the biodiversity of fucoidan extracts, from dif-
ferent seaweeds, and to retain the structural features of 
significance for specific bioactivity of fucoidan extracts. 
Furthermore, the determination and clarification of the 
structural characteristics responsible for antitumor activi-
ties of fucoidan will be essential for its potential as a 
marine-origin drug.
5. Experimental Section
5.1. Materials
FE 1 was purchased from Marinova, whereas Fucoidan Extract 
2 (FE 2 – batch SLBC6348V) and Fucoidan Extract 3 (FE 3 – batch 
081M7672V), were purchased from Sigma-Aldrich, all used as 
received. The human vascular endothelial growth factor ELISA 
kit was purchased from Peprotech (Rochy Hill, NJ, USA) and kept 
at 4 °C until used. Phalloidin-Tetramethylrhodamine B isothiocy-
anate (Texas Red – Phalloidin), DTAF were both purchased from 
Sigma. 4,6-Diamidino-2-phenyindole, dilactate (DAPI) was pur-
chased from Biotium (Hayward, CA, USA).
5.2. Biological Assays
5.2.1. Cell Expansion
Human fibroblasts (MRC-5 cell line) and pulmonary microvas-
cular endothelial cells (HPMEC-ST1.6R cell line) were used as 
noncancer cells. Fibroblast cells were cultured in D-MEM low 
glucose medium (Sigma-Aldrich) supplemented with 10% FBS 
(Alfagene) and Pen/Strep (100 U/100 g mL−1; Life Technologies). 
Fibroblasts were used at passages 14–16. Endothelial cells were 
cultured in M199 medium (Sigma-Aldrich) supplemented with 
20% FBS (Alfagene), 2 × 10−3 m Glutamax (Life Technologies), 
Pen/Strep (100 U/100 g mL−1; Life Technologies), endothelial 
cell growth supplement (ECGS – 25 µg mL−1; Becton Dickinson). 
Endothelial cells were used at passages 38–40.
Human breast adenocarcinoma cells (MCF-7 and MDA-MB-231 
cell lines) were used to assess the effect of different fucoidan’s 
concentrations over these cancer cells models. Both cell lines 
were cultured in D-MEM high glucose medium (Sigma-Aldrich) 
supplemented with 10% Fetal Bovine Serum (FBS) (Alfagene), 
Pen/Strep (100 U/100 g mL−1; Life Technologies) and 1% MEM 
sodium pyruvate solution 100 × 10−3 m (Alfagene). The MCF-7 cell 
line was used at passages 16–18, whereas the MDA-MB-231 cell 
line was used at passages 42–44.
The four types of cells were incubated at 37 °C in a humidified 
5% CO2 atmosphere. Media were exchanged every 2–3 days until 
cells reached a 90% confluence.
5.2.2. Cell Culture
Noncancer and cancer cells were harvested and 15 000 cells were 
cultured in 24 well-plates. The cells were left to adhere for 4 h and, 
after that, fucoidan extracts were added to adherent cells. Fucoidan 
extracts were dissolved in the culture medium at different concen-
trations: for FE 1 the concentrations tested were 0.1, 0.5, 1, 2, 3, 4, 
and 5 mg mL−1, whereas for FE 2 and FE 3 the concentrations were 
0.1, 0.2, 0.3, 0.4, and 0.5 mg mL−1. For all the assays a positive control 
was performed (no fucoidan in the culture medium). Each experi-
mental condition was tested in triplicate and two independent 
assays were performed for each type of cells and fucoidan extracts.
5.2.3. Cell Viability
The metabolic activity of noncancer and cancer cells, cultured 
at different fucoidan extracts’ concentrations and time points, 
was determined by the MTS assay (CellTiter 96 AQueous One 
Solution, Promega). The MTS assay is a colorimetric method 
commonly used for cytotoxicity assays or for determining the 
number of viable cells in proliferation. Basically, the quantity 
of formazan product is directly proportional to the number of 
living cells in culture.[45] At days 1, 2, and 3, the culture medium 
was removed and the testing conditions were rinsed with sterile 
Phosphate-Buffered Saline (PBS). A mixture of culture medium 
(without FBS and phenol red) and MTS reagent (5:1 ratio) was 
added to each well and left to incubate for 3 h, at 37 °C, in a 
humidified 5% CO2 atmosphere. Thereafter, the absorbance of 
the MTS reaction medium from each sample was read in tripli-
cate at 490 nm in a microplate reader (Synergy HT, Bio-TEK). All 
experiments were performed in triplicate.
5.2.4. DTAF-Labeled Fucoidan and Morphological 
Observation
DTAF-labeled fucoidan was prepared as described elsewhere.[46,47] 
Briefly, DTAF was reconstituted in methanol and kept at 4 °C 
until further use. A 0.2 mg mL−1 solution of FE 1 and FE 2 was left 
to stir with DTAF for 3 h (20 µg mL−1). The procedure described 
in Sections 5.2.2 and 5.2.3 were followed, but was added DTAF-
labeled FE 1 and FE 2 instead of the pure FE. At days 1, 2, and 3, 
samples were washed with PBS, fixed for 30 min with 10% for-
malin, washed again with PBS and kept in PBS at 4 °C.
To evaluate whether and where fucoidan has been internalized 
by the different cell types, the nucleus and cytoskeleton of 
those cells were also fluorescent labeled. First, a blocking step 
was performed with 3% Bovine Serum Albumin (BSA) in PBS 
for 30 min. Then, the BSA solution was removed and cells were 
washed with PBS. After that, Phalloidin-Tetramethylrhodamine 
B isothiocyanate (1:200 in PBS) was added and left incubating 
for 45 min. Another washing step was performed and the same 
samples were incubated with 4,6-Diamidino-2-phenyindole, 
dilactate (1:1000 in PBS) for 15 min. Cell were washed with PBS 
and observed in a transmitted and reflected light microscope 
with Apotome 2 (Axio Imager Z1m, Zeiss).
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5.3. Fucoidan Characterization
5.3.1. Molecular Weight Determination by Gel 
Permeation Chromatography
GPC measurements were performed with a Malvern Viscotek 
TDA 305 with refractometer, right angle light scattering and vis-
cometer detectors on a set of four columns: precolumn Suprema 
5 µm 8 × 50 S/N 3111265, Suprema 30 Å 5 µm 8 × 300 S/N 
3112751, Suprema 1000 Å 5 µm 8 × 300 S/N 3112851 PL, and 
Aquagel-OH MIXED 8 µm 7.5 × 300 S/N 8M-AOHMIX-46-51, 
with refractive index detection (RI-Detector 8110, Bischoff). 
The system was kept at 30 °C using 0.1 m NaN3, 0.01 m NaH2PO4 
(pH = 6.6) as eluent at rate of 1 mL min−1. The elution times of 
the RI detector signal were calibrated with a commercial polysac-
charide set from Varian that contains 10 Pullulans with narrow 
polydispersity and Mp (molecular mass at the peak maximum) 
ranging from 180 Da to 708 kDa.
5.3.2. Depolymerization of Fucoidan Extract FE1 
by Acid Hydrolysis
FE 1 was hydrolyzed to obtain lower molecular weight fucoidan, 
following a procedure described previously.[38] Briefly, partially 
hydrolyzed fucoidan was obtained by hydrolyzing FE 1 (20 mg) 
with 1 mL of 0.01 m HCl at 100 °C for 10 min, followed by neu-
tralization with 1 mL of 0.01 m NaOH. The resulting hydrolyzed 
fucoidan FE1* was analyzed by GPC. A control was performed by 
dissolving FE 1 (20 mg) in 1 mL of 0.01 m HCl without heat treat-
ment, followed by neutralization with 1 mL of 0.01 m NaOH. The 
procedures described in Sections 5.2.2 and 5.2.3 were followed, 
but, instead of FE 1, hydrolyzed fucoidan was added at dif-
ferent concentrations (0.2, 0.5, and 1 mg mL−1). A positive control 
with untreated cells and controls with HCl and NaOH without 
fucoidan were also performed.
5.3.3. Carbohydrates Composition: Determination 
of Neutral and Acidic Monosaccharides
Neutral monosaccharides were determined as alditol acetates 
as described elsewhere.[48] Briefly a prehydrolysis of fucoidans 
was performed, with 72% sulfuric acid for 3 h at room tempera-
ture (RT). Afterward, the fucoidan extracts were submitted to a 
hydrolysis with sulfuric acid 1 m at 100 °C for 2.5 h. 2-Deoxyglu-
cose was used as an internal standard. Monosaccharides were 
reduced with sodium borohydride and acetylated by acetic anhy-
dride using methylimidazole as a catalyst. The formed alditol 
acetate derivatives were analyzed by gas chromatography (GC) 
with a 30 m column DB-225 (J&W Scientific, Folsom, CA, USA), 
internal diameter, and film thickness of 0.25 and 0.15 mm, 
respectively, and using a flame ionization detector (Perkin Elmer, 
Clarus 400). The hydrolysis of all samples was performed in 
duplicate and each one was injected twice. A third analysis was 
done for the few samples with higher variability. Uronic acids 
were quantified by a modification of the 3-phenylphenol col-
orimetric method.[48] Samples were prepared by hydrolysis with 
72% sulfuric acid for 3 h at RT followed by 1 h in sulfuric acid 1 m 
at 100 °C. A calibration curve was made with d-galacturonic acid. 
The hydrolysis and analysis of the samples was done in triplicate.
5.3.4. NMR Spectroscopy
NMR experiments were acquired on a Bruker AVANCE 400 spec-
trometer using D2O as solvent. The residual HOD signal was used 
as reference for the chemical shifts that are reported in ppm. 
Mnova Software 9.0 (Mestrelab Research) was used for spectral 
processing. Sulfation position and branching was qualitatively 
analyzed based on the chemical shifts described previously.[26,27]
5.3.5. Sulfation Degree: Ester Sulfate Determination
The content of ester sulfates in the fucoidan extracts was deter-
mined by the turbidimetric method proposed by Dodgson 
and Price.[49,50] The fucoidan extracts were accurately weighed 
(usually 2–4 mg) and dissolved in the respective amount of 
N-hydrochloric acid 1 m. The mixture was submitted to a hydrol-
ysis at 105–110 °C for 5 h. A portion (0.2 mL) was transferred to 
a tube containing 3.8 mL of 3% (w/v) trichloroacetic acid. Barium 
chloride-gelatin reagent (1 mL) was added and, after mixing, 
the whole was kept at RT for 15–20 min. The barium chloride-
gelatin reagent was previously prepared by mixing gelatin (1 g) 
with 200 mL of hot water (60–70 °C) and was allowed to stand at 
4 °C overnight. Barium chloride (1 g) was dissolved in the semi-
gelatinous fluid and the resultant cloudy solution was allowed 
to stand for 2–3 h before use. The solution was then analyzed at 
360 nm (Jenway 6405 UV/Vis) against reagent blank containing 
distilled water instead of sample.
A second 0.2 mL portion of the hydrolysate was mixed with 
3.8 mL of trichloroacetic acid, as described above, and with 
1 mL of gelatin solution (i.e., containing no barium chloride). 
The extinction of this “control” solution was then measured at 
360 nm against a reagent blank consisting on distilled water 
instead of sample and 1 mL of gelatin solution. The concentration 
of sulfate esters was determined by building a K2SO4 calibration 
curve, containing between 20 and 200 µg of SO42− ion.
5.3.6. Desulfation
For polysaccharide desulfation, 10 mg were dissolved in 1.8 mL of 
dried dimethyl sulfoxide. Then, 0.1 mL pyridine was added, fol-
lowed by 13 mg of pyromellitic acid, 12 mg of NaF, and 0.2 mL 
of pyridine. The mixture was stirred at 120 °C for 3 h, cooled and 
poured into 1 mL of 3% of NaHCO3 aqueous solution. The solu-
tion containing the desulfated polysaccharide was dialysed and 
freeze-dried. The procedure was repeated in order to guarantee 
the complete desulfation. Afterward, the desulfated polysaccha-
ride was submitted to methylation analysis.[51,52]
5.3.7. Methylation Analysis
Glycosidic-substitution analysis was determined by gas chroma-
tography-quadrupole mass spectrometry (GC-qMS) of the par-
tially methylated alditol acetates based on Ciucanu and Kerek[53] 
and Coelho et al.[54] The native and desulfated samples (1–2 mg) 
were dissolved in 1 mL of anhydrous dimethylsulfoxide, and then 
powdered NaOH (40 mg) were added under an argon atmosphere. 
The samples were methylated with CH3I (80 µL) during 20 min 
with stirring, following by a second and third addition of 80 µL 
CH3I and stirring for another 20 min. CHCl3/MeOH (1:1, v/v, 3 mL) 
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was added, and the solution was dialyzed (membrane with a 
pore diameter of 12–14 kDa) against 50% EtOH. The dialysate 
was evaporated to dryness and the material was remethylated 
using the same procedure. The remethylated material was hydro-
lyzed with 2 m TFA (1 mL) at 120 °C for 1 h, and then reduced and 
acetylated as previously described for neutral sugar analysis 
(using NaBD4 instead of NaBH4). The partially methylated alditol 
acetates were separated and analyzed by GC-qMS (GC-2010 Plus, 
Shimadzu). The GC was equipped with a DB-1 (J&W Scientific, 
Folsom, CA, USA) capillary column (30 m length, 0.25 mm of 
internal diameter, and 0.10 µm of film thickness). The samples 
were injected in “split” mode with the injector temperature at 
250 °C. The temperature program used was as follows: (1) an 
initial temperature of 80 °C; (2) an increase of 7.5 °C min−1 until 
140 °C and a hold time of 5 min; (3) an increase of 0.2 °C min−1 
until 143.2 °C; (4) an increase of 12 °C min−1 until 200 °C; (5) an 
increase of 50 °C min−1 until 250 °C and a hold time of 5 min. The 
helium carrier gas had a total flow rate of 8.5 mL min−1. The GC 
was connected to GCMS-QP 2010 Ultra Shimadzu mass quadru-
pole selective detector operating with an electron impact mode 
at 70 eV and scanning the range m/z 50–700 in a 1 s cycle in a 
full scan mode acquisition.
5.4. Statistical Analysis
Statistical analysis was performed using Graph Pad Prism 
Software. Differences between the different conditions of 
the cellular assays were analyzed using nonparametric test 
(Kruskal–Wallis test) and a p < 0.05 was considered significant. 
Data are presented as mean ± standard deviations.
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